ATE504292T1 - Orale formulierung der wasserfreien olanzapin- form i - Google Patents

Orale formulierung der wasserfreien olanzapin- form i

Info

Publication number
ATE504292T1
ATE504292T1 AT06841451T AT06841451T ATE504292T1 AT E504292 T1 ATE504292 T1 AT E504292T1 AT 06841451 T AT06841451 T AT 06841451T AT 06841451 T AT06841451 T AT 06841451T AT E504292 T1 ATE504292 T1 AT E504292T1
Authority
AT
Austria
Prior art keywords
core
olanzapine
anhydrous
salt
functional polymer
Prior art date
Application number
AT06841451T
Other languages
German (de)
English (en)
Inventor
Martoen Ignacio Doeez
Perez Carmen Ebeda
Alba Pablo Pablo
Original Assignee
Lesvi Laboratorios Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38468505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE504292(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lesvi Laboratorios Sl filed Critical Lesvi Laboratorios Sl
Application granted granted Critical
Publication of ATE504292T1 publication Critical patent/ATE504292T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT06841451T 2005-12-26 2006-12-19 Orale formulierung der wasserfreien olanzapin- form i ATE504292T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200503183A ES2279715B1 (es) 2005-12-26 2005-12-26 Formulacion oral de olanzapina.
US75410405P 2005-12-27 2005-12-27
PCT/EP2006/069905 WO2007074110A1 (en) 2005-12-26 2006-12-19 Oral formulation of anhydrous olanzapine form i

Publications (1)

Publication Number Publication Date
ATE504292T1 true ATE504292T1 (de) 2011-04-15

Family

ID=38468505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06841451T ATE504292T1 (de) 2005-12-26 2006-12-19 Orale formulierung der wasserfreien olanzapin- form i

Country Status (13)

Country Link
US (1) US8962018B2 (es)
EP (1) EP1965773B1 (es)
JP (1) JP2009521518A (es)
KR (1) KR20080080230A (es)
AT (1) ATE504292T1 (es)
CY (1) CY1111666T1 (es)
DE (1) DE602006021231D1 (es)
DK (1) DK1965773T3 (es)
ES (2) ES2279715B1 (es)
PL (1) PL1965773T3 (es)
PT (1) PT1965773E (es)
SI (1) SI1965773T1 (es)
WO (1) WO2007074110A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
WO2012014012A1 (es) * 2010-07-27 2012-02-02 Laboratorios Andrómaco S.A. Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
PL2612681T3 (pl) * 2010-08-31 2019-09-30 Toray Industries, Inc. Środek powlekający do stałego preparatu farmaceutycznego, formulacja farmaceutyczna filmu i powlekany stały preparat farmaceutyczny
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
CN104546807B (zh) * 2015-01-21 2020-09-01 齐鲁制药有限公司 奥氮平口腔速溶膜剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
EP0771339B1 (en) 1994-07-12 2003-10-15 BPSI Holdings, Inc. Dry moisture barrier film coating composition, method of coating substrates using the same and pharmaceutical tablets coated therewith
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5631250A (en) 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
US5843477A (en) * 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
JP4530664B2 (ja) 2001-12-24 2010-08-25 サン・ファーマシューティカル・インダストリーズ・リミテッド ２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
MXPA04008100A (es) * 2002-02-21 2005-06-17 Biovail Lab Int Srl Formulaciones de liberacion modificada de al menos una forma de tramadol.
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
ATE500258T1 (de) 2002-05-31 2011-03-15 Sandoz Ag Verfahren zur herstellung von olanzapin form i
SI21303A (sl) 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
WO2004058222A1 (en) 2002-12-20 2004-07-15 St. James Associates Llc/Faber Research Series High pressure compaction for pharmaceutical formulations
WO2005009407A2 (en) 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation

Also Published As

Publication number Publication date
DK1965773T3 (da) 2011-07-25
EP1965773B1 (en) 2011-04-06
SI1965773T1 (sl) 2011-09-30
EP1965773A1 (en) 2008-09-10
DE602006021231D1 (de) 2011-05-19
US20080311203A1 (en) 2008-12-18
KR20080080230A (ko) 2008-09-02
WO2007074110A1 (en) 2007-07-05
ES2279715B1 (es) 2008-06-01
PL1965773T3 (pl) 2011-11-30
ES2279715A1 (es) 2007-08-16
ES2359647T3 (es) 2011-05-25
PT1965773E (pt) 2011-07-12
US8962018B2 (en) 2015-02-24
JP2009521518A (ja) 2009-06-04
CY1111666T1 (el) 2015-10-07

Similar Documents

Publication Publication Date Title
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
EP2609064A4 (en) PHARMACEUTICAL COMPOSITIONS WITH POH DERIVATIVES
UA104902C2 (uk) Фармацевтичні композиції для запобігання зловживанню лікарськими препаратами
AR065096A1 (es) Preparacion solida
CY1115150T1 (el) Βοηθηματα διαλυτοποιησης για τη χορηγηση πεπτιδιων απο το στομα, τα οποια περιεχουν διγουανιδη
DK1856090T3 (da) Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
PE20050286A1 (es) Formulacion de multiparticulas que comprenden oxicodona
CL2008003789A1 (es) Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer.
CL2013001885A1 (es) Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
BR112012018374A2 (pt) derivados de ácido carboxílico de pirrolidina ou tiazolidina, composição farmacêutica e métodos para uso no tratamento de distúrbios metabólicos como agonistas de receptor 43 acoplado à proteína g (gpr43).
NO20075111L (no) Farmasoytisk sammensetning
MA32622B1 (fr) Derives de carbonate de quinuclidine et composition medicinale les comprenant
HN2006007884A (es) Derivados de oxiindol
EA201190142A1 (ru) Производные пиразола, используемые в качестве антагонистов рецептора ccr4
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
BRPI0814891A2 (pt) Composição farmacêutica contendo composto oticamente ativo tendo atividade agonista de receptor de trombopoietina, e intermediário do mesmo.
UA107353C2 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
CL2011000044A1 (es) Uso de una composicion farmaceutica oral que comprende al menos un antagonista opioide seleccionado de naloxona, naltrexona, nalbufino o sus sales, adicionalmente puede comprender al menos un agonista opioide, tal como oxicodona, morfina u otros, para el tratamiento de la retencion urinaria.
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
UY31839A (es) Compuestos
ATE504292T1 (de) Orale formulierung der wasserfreien olanzapin- form i
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
DK1994926T3 (da) Valsartanformuleringer
RU2008147216A (ru) Жидкая лекарственная композиция

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1965773

Country of ref document: EP